HUE054453T2 - Új peptidek és peptidkombinációk az emlõrák és más ráktípusok elleni immunterápiában történõ használatra - Google Patents
Új peptidek és peptidkombinációk az emlõrák és más ráktípusok elleni immunterápiában történõ használatraInfo
- Publication number
- HUE054453T2 HUE054453T2 HUE16802063A HUE16802063A HUE054453T2 HU E054453 T2 HUE054453 T2 HU E054453T2 HU E16802063 A HUE16802063 A HU E16802063A HU E16802063 A HUE16802063 A HU E16802063A HU E054453 T2 HUE054453 T2 HU E054453T2
- Authority
- HU
- Hungary
- Prior art keywords
- cancers
- breast cancer
- novel peptides
- peptide combinations
- against breast
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title 2
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562270968P | 2015-12-22 | 2015-12-22 | |
| GBGB1522667.3A GB201522667D0 (en) | 2015-12-22 | 2015-12-22 | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE054453T2 true HUE054453T2 (hu) | 2021-09-28 |
Family
ID=55311455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16802063A HUE054453T2 (hu) | 2015-12-22 | 2016-11-29 | Új peptidek és peptidkombinációk az emlõrák és más ráktípusok elleni immunterápiában történõ használatra |
Country Status (27)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| NZ754222A (en) | 2016-12-08 | 2022-02-25 | Immatics Biotechnologies Gmbh | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| RS61817B1 (sr) | 2017-07-14 | 2021-06-30 | Immatics Biotechnologies Gmbh | Poboljšani polipeptidni molekul sa dvojnom specifičnošću |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| AU2018395397A1 (en) * | 2017-12-28 | 2020-08-06 | Gritstone Bio, Inc. | Antigen-binding proteins targeting shared antigens |
| WO2019157298A1 (en) | 2018-02-09 | 2019-08-15 | Immatics US, Inc. | Methods for manufacturing t cells |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| JP7444376B2 (ja) * | 2018-09-21 | 2024-03-06 | 国立大学法人 東京大学 | がんの予後判定方法 |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| TWI872076B (zh) | 2019-05-27 | 2025-02-11 | 美商英麥提克斯股份有限公司 | 病毒載體及其在授受性細胞療法之應用 |
| WO2020245326A1 (en) | 2019-06-06 | 2020-12-10 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| CA3168729A1 (en) | 2020-02-24 | 2021-09-02 | Melinda MATA | Methods for expanding t cells for the treatment of cancer and related malignancies |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| CN111979323A (zh) * | 2020-08-28 | 2020-11-24 | 深圳裕策生物科技有限公司 | 用于预测肿瘤免疫治疗效果的生物标志物检测方法及系统 |
| WO2022147029A2 (en) | 2020-12-31 | 2022-07-07 | Immatics US, Inc. | Cd8 polypeptides, compositions, and methods of using thereof |
| EP4277999A4 (en) * | 2021-01-14 | 2024-12-18 | Loma Linda University | METHODS FOR EVALUATION OF EARLY STAGE ORAL SQUAMOUS CELL CARCINOMA |
| CA3217739A1 (en) | 2021-05-05 | 2022-11-10 | Sebastian Bunk | Bma031 antigen binding polypeptides |
| CN113528436B (zh) * | 2021-08-04 | 2023-01-17 | 苏州大学 | 基于淋巴细胞的同源靶向性人工抗原呈递细胞及其构建和应用 |
| JP2024534825A (ja) | 2021-08-24 | 2024-09-26 | イマティクス ユーエス，アイエヌシー． | 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択 |
| WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| WO2023081925A1 (en) | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| CN114685641B (zh) * | 2022-02-25 | 2024-03-08 | 西安交通大学医学院第一附属医院 | 一种抑制brca1/bard1复合体结合的多肽及其应用和防治癌症的药物 |
| WO2023212697A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| US20230348561A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| EP4519418A1 (en) | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN115537402B (zh) * | 2022-10-11 | 2024-12-10 | 湖北文理学院 | Tm9sf1基因调控肺系细胞的方法以及应用 |
| KR20240158819A (ko) * | 2023-04-26 | 2024-11-05 | 한국과학기술원 | 섬유아세포 활성화 단백질의 면역우세 에피토프 펩타이드 및 이의 용도 |
| US20250134931A1 (en) | 2023-11-01 | 2025-05-01 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| CN118311277B (zh) * | 2024-06-11 | 2024-12-31 | 北京卫未科学技术有限公司 | 一种用于癌症早筛和辅助诊断的试剂盒及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| DD147855A5 (de) | 1978-12-22 | 1981-04-22 | Biogen Nv | Verfahren zur erzeugung mindestens eines hbv-antigenwirkung aufweisenden polypeptids |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| FI955798L (fi) | 1993-06-03 | 1996-02-01 | Therapeutic Antibodies Inc | Terapeuttiset vasta-ainefrangmentit |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| AU1394497A (en) | 1996-01-17 | 1997-08-11 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US20030211510A1 (en) * | 1999-06-30 | 2003-11-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US7211649B1 (en) * | 1999-07-02 | 2007-05-01 | Ana Mar Medical Ab | Cartilage intermediate layer protein |
| CA2490909A1 (en) | 1999-12-01 | 2001-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2393730A1 (en) * | 1999-12-13 | 2001-06-14 | Epimmune Inc. | Hla class i a2 tumor associated antigen peptides and vaccine compositions |
| WO2001046394A2 (en) * | 1999-12-21 | 2001-06-28 | Sugen, Inc. | Mammalian protein phosphatases |
| EP2316950A1 (en) | 2000-03-27 | 2011-05-04 | Technion Research and Development Foundation, Ltd. | Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| AU7524601A (en) | 2000-06-05 | 2001-12-17 | Sunol Molecular Corp | T cell receptor fusions and conjugates and methods of use thereof |
| EP1306431B1 (en) | 2000-07-31 | 2008-03-19 | Green Peptide Co., Ltd. | Tumor antigen |
| WO2002016939A2 (en) * | 2000-08-18 | 2002-02-28 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer and screening for cancer modulators |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| CA2476625A1 (en) | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
| EP1549748B1 (en) | 2002-10-09 | 2014-10-01 | Immunocore Ltd. | Single chain recombinant t cell receptors |
| WO2004044004A2 (en) | 2002-11-09 | 2004-05-27 | Avidex Limited | T cell receptor display |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| WO2005007090A2 (en) * | 2003-07-03 | 2005-01-27 | President And Fellows Of Harvard College | Inhibitors of the map kinase pathway |
| JP2008505648A (ja) | 2004-07-07 | 2008-02-28 | メタボレックス インコーポレーティッド | 糖尿病およびインスリン抵抗性の診断および治療の方法 |
| SI1806359T1 (sl) * | 2005-09-05 | 2010-06-30 | Immatics Biotechnologies Gmbh | S tumorjem povezani peptidi ki se vežejo brez izjeme na molekule humanega levkocitnega antigena HLA razred II |
| CA2703585A1 (en) | 2007-10-23 | 2009-04-30 | The Regents Of The University Of Colorado | Competitive inhibitors of invariant chain expression and/or ectopic clip binding |
| KR100999043B1 (ko) * | 2007-12-04 | 2010-12-09 | 한국생명공학연구원 | 융합 단백질을 사용하지 않는 인간 단백질 타이로신탈인산화 효소의 활성 도메인 대량 생산 방법 |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| ES2532896T5 (es) | 2008-05-14 | 2018-03-20 | Immatics Biotechnologies Gmbh | Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| EP2632955A1 (en) | 2010-10-26 | 2013-09-04 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| WO2014010231A1 (en) * | 2012-07-10 | 2014-01-16 | Oncotherapy Science, Inc. | Kif20a epitope peptides for th1 cells and vaccines containing the same |
| MX364370B (es) * | 2012-07-12 | 2019-04-24 | Persimmune Inc | Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas. |
| GB201214007D0 (en) * | 2012-08-07 | 2012-09-19 | Scancell Ltd | Anti-tumour immune responses to modified self-epitopes |
| ES2603589T3 (es) | 2012-11-08 | 2017-02-28 | F. Hoffmann-La Roche Ag | Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas |
| EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
| TWI777196B (zh) * | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（五） |
| GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
-
2015
- 2015-12-22 GB GBGB1522667.3A patent/GB201522667D0/en not_active Ceased
-
2016
- 2016-11-29 LT LTEP16802063.4T patent/LT3394084T/lt unknown
- 2016-11-29 EP EP16802063.4A patent/EP3394084B1/en active Active
- 2016-11-29 CA CA3009286A patent/CA3009286A1/en active Pending
- 2016-11-29 CR CR20200556A patent/CR20200556A/es unknown
- 2016-11-29 AU AU2016375806A patent/AU2016375806B2/en not_active Ceased
- 2016-11-29 PE PE2018000415A patent/PE20181800A1/es unknown
- 2016-11-29 KR KR1020187020794A patent/KR20180089522A/ko not_active Ceased
- 2016-11-29 HU HUE16802063A patent/HUE054453T2/hu unknown
- 2016-11-29 CR CR20200557A patent/CR20200557A/es unknown
- 2016-11-29 JP JP2018521114A patent/JP2019510465A/ja active Pending
- 2016-11-29 BR BR112018009980-5A patent/BR112018009980A2/pt not_active Application Discontinuation
- 2016-11-29 PT PT168020634T patent/PT3394084T/pt unknown
- 2016-11-29 SG SG11201801384YA patent/SG11201801384YA/en unknown
- 2016-11-29 EP EP21162594.2A patent/EP3875467A3/en not_active Withdrawn
- 2016-11-29 ES ES16802063T patent/ES2867880T3/es active Active
- 2016-11-29 CR CR20180135A patent/CR20180135A/es unknown
- 2016-11-29 DK DK16802063.4T patent/DK3394084T3/da active
- 2016-11-29 MD MDE20181036T patent/MD3394084T2/ro not_active IP Right Cessation
- 2016-11-29 WO PCT/EP2016/079059 patent/WO2017108345A1/en not_active Ceased
- 2016-11-29 RS RS20210548A patent/RS61787B1/sr unknown
- 2016-11-29 MA MA42020A patent/MA42020A1/fr unknown
- 2016-11-29 US US16/065,681 patent/US10213499B2/en active Active
- 2016-11-29 EA EA201891465A patent/EA201891465A1/ru unknown
- 2016-11-29 CN CN201680075076.8A patent/CN108602855A/zh active Pending
- 2016-11-29 SI SI201631179T patent/SI3394084T1/sl unknown
- 2016-11-29 MX MX2018005273A patent/MX2018005273A/es unknown
- 2016-11-29 PL PL16802063T patent/PL3394084T3/pl unknown
- 2016-11-29 SG SG10202005950XA patent/SG10202005950XA/en unknown
- 2016-11-29 CR CR20200555A patent/CR20200555A/es unknown
- 2016-11-29 MA MA44693A patent/MA44693B1/fr unknown
- 2016-11-29 MA MA44101A patent/MA44101B1/fr unknown
- 2016-12-20 US US15/384,963 patent/US10064929B2/en active Active
- 2016-12-22 TW TW105142661A patent/TWI655205B/zh not_active IP Right Cessation
-
2018
- 2018-04-11 CO CONC2018/0003860A patent/CO2018003860A2/es unknown
-
2020
- 2020-12-16 AU AU2020289763A patent/AU2020289763B2/en not_active Ceased
-
2021
- 2021-04-29 JP JP2021076900A patent/JP7535974B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE054453T2 (hu) | Új peptidek és peptidkombinációk az emlõrák és más ráktípusok elleni immunterápiában történõ használatra | |
| HUE049937T2 (hu) | Új peptidek és peptidkombinációk az epiteliális petefészekrák és más ráktípusok elleni immunterápiában történõ használatra | |
| HUE053657T2 (hu) | Peptidek és peptidkombinációk a prosztatarák és más ráktípusok elleni immunterápiában történõ használatra | |
| IL258599A (en) | New peptides and a combination of peptides used in immunotherapy against breast cancer and other types of cancer | |
| GB201511792D0 (en) | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers | |
| IL256189A (en) | New peptides and combinations of peptides used in immunotherapy against ovarian cancer and other types of cancer | |
| SG10202101368WA (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
| SG10202001665QA (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
| IL269741A (en) | Peptides and combination thereof for use in the immunotherapy against cancers | |
| GB201517538D0 (en) | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | |
| ZA201707810B (en) | Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | |
| SG10202001485UA (en) | Novel peptides and combination of peptides for use in immunotherapy against various tumors | |
| GB201604458D0 (en) | Peptides and combination of peptides for use in immunotherapy against cancers | |
| GB201604490D0 (en) | Peptides combination of peptides for use in immunotherapy against cancers | |
| IL269813A (en) | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers | |
| IL258609A (en) | New peptides and a combination of peptides for use in immunotherapy against several types of cancer | |
| HUE046641T2 (hu) | Új peptidek és peptidkombinációk hepatocelluláris karcinóma (HCC) és más rákok elleni immunoterápiában történõ alkalmazásra | |
| ZA201801013B (en) | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | |
| IL263257A (en) | Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |